Inhibitory strategies targeting angiotensin II signaling in PVAT, such as treatment with AT1R blockers or ACE inhibitors, may be beneficial for the prevention and treatment of MetS-related organ injury. The gene discussed is ACE; the disease is metabolic syndrome.